Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

被引：37
|
作者：
Wang, Zhan [1 ]
Chen, Juan [2 ,3 ]
Zhong, Mei-Zuo [1 ]
Huang, Juan [4 ]
Hu, Yuan-Ping [4 ]
Feng, De-Yun [5 ]
Zhou, Zhi-Jiao [6 ]
Luo, Xiao [7 ]
Liu, Zhao-Qian [2 ,3 ]
Jiang, Wu-Zhong [1 ]
Zhou, Wei-Bing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
[4] Hunan Prov Clin Meditech Res Ctr Breast Canc, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Pathol, Changsha 410013, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Dept Pain, Changsha 410013, Hunan, Peoples R China
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2017年 / 79卷 / 03期
基金：
中国国家自然科学基金;
关键词：
ANLN; Breast cancer; Anthracycline; Prognosis; BINDING PROTEIN ANILLIN; DNA ADDUCTS; CYCLIN D1; ADJUVANT THERAPY; DOXORUBICIN; REPAIR; CYCLOPHOSPHAMIDE; EXPRESSION; RECOMBINATION; ACTIVATION;
D O I：
10.1007/s00280-017-3248-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
引用
收藏
页码：535 / 543
页数：9
相关论文
共 50 条
  • [21] Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: A narrative review
    Simoes, Ricardo
    Silva, Luciana Maria
    Valle Mussi Cruz, Andre Luiz
    Fraga, Vanessa Gomes
    Sabino, Adriano de Paula
    Gomes, Karina Braga
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 107 : 989 - 996
  • [22] Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer
    Ishitobi, Makoto
    Komoike, Yoshifumi
    Motomura, Kazuyoshi
    Koyama, Hiroki
    Inaji, Hideo
    ONCOLOGY, 2010, 78 (3-4) : 213 - 219
  • [23] Tumor Topoisomerase II Alpha Status and Response to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
    Nikolenyi, Aliz
    Suekoesd, Farkas
    Kaizer, Laszlo
    Csoergo, Erika
    Voeroes, Andras
    Uhercsak, Gabriella
    Ormandi, Katalin
    Lazar, Gyoergy
    Thurzo, Laszlo
    Brodowicz, Thomas
    Kahan, Zsuzsanna
    ONCOLOGY, 2011, 80 (3-4) : 269 - 277
  • [24] Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy
    Song, Zhiguo
    Wang, Yong
    Xiao, Qinghuan
    Yu, Zhaojin
    Zhao, Lin
    Wu, Huizhe
    Sun, Mingli
    Chai, Zhangguo
    Hou, Ping
    Geng, Xiaoqiang
    Liu, Wensi
    Wei, Minjie
    ONCOLOGY LETTERS, 2018, 16 (05) : 5621 - 5630
  • [25] Cardiac Tolerability of Concurrent Administration of Trastuzumab and Anthracycline-Based Regimen as Adjuvant Chemotherapy for Breast Cancer
    Watanabe, Naoki
    Otsuka, Shoko
    Sasaki, Yoko
    Shimojima, Reiko
    Wani, Yoji
    Uchino, Kaori
    BREAST CARE, 2014, 9 (01) : 46 - 51
  • [26] Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors
    Serrano, Jose M.
    Mata, Rebeca
    Gonzalez, Iria
    Del Castillo, Silvia
    Muniz, Javier
    Morales, Luis J.
    Espinosa, Maria Jesus
    Moreno, Fernando
    Jimenez, Rosa
    Cristobal, Carmen
    Graupner, Catherine
    Talavera, Pedro
    Landaluce, Carlos Gutierez
    Curcio, Alejandro
    Alonso, Javier
    Guerra, Juan A.
    Alonso, Joaquin J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 382 : 52 - 59
  • [27] Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer
    Chavez-MacGregor, Mariana
    Brown, Erika
    Lei, Xiudong
    Litton, Jennifer
    Meric-Bernstram, Funda
    Mettendorf, Elizabeth
    Hernandez, Leonel
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Gonzalez-Angulo, Ana Maria
    CANCER, 2012, 118 (02) : 326 - 332
  • [28] The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer
    Nolan, Luke
    Darby, Angela
    Boleti, Katia
    Simmonds, Peter
    BREAST, 2011, 20 (02) : 151 - 154
  • [29] The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy
    Kawachi, Kae
    Sasaki, Takeshi
    Murakami, Ayumi
    Ishikawa, Takashi
    Kito, Ayako
    Ota, Ikuko
    Shimizu, Daisuke
    Nozawa, Akinori
    Nagashima, Yoji
    Machinami, Rikuo
    Aoki, Ichiro
    PATHOLOGY RESEARCH AND PRACTICE, 2010, 206 (03) : 156 - 162
  • [30] Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy
    Dranitsaris, G
    Tran, TM
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) : 2174 - 2180
12345